Published in final edited form as:

J Matern Fetal Neonatal Med. 2014 November ; 27(17): 1728–1733. doi:10.3109/14767058.2013.876622.

Haptoglobin Phenotype and Abnormal Uterine Artery Doppler in a Racially Diverse Cohort

Tracey L. Weissgerber¹, Paula L. McGee², Leslie Myatt³, John C. Hauth⁴, Michael W. Varner⁵, Ronald J. Wapner⁶, John M. Thorp Jr.⁷, Brian M. Mercer⁸, Alan M. Peaceman⁹, Susan M. Ramin¹⁰, Philip Samuels¹¹, Anthony Sciscione¹², Margaret Harper¹³, George Saade¹⁴, Yoram Sorokin¹⁵, and for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network*

¹Magee-Womens Research Institute, Department of Obstetrics, Gynecology and Reproductive Science, University of Pittsburgh, Pittsburgh, PA

²The George Washington University Biostatistics Center, Washington, DC

³Departments of Obstetrics and Gynecology of University of Cincinnati, Cincinnati, OH

⁴University of Alabama at Birmingham, Birmingham, AL

⁵University of Utah, Salt Lake City, UT

⁶Columbia University, New York, NY

⁷University of North Carolina at Chapel Hill, Chapel Hill, NC

⁸Case Western Reserve University-MetroHealth Medical Center, Cleveland, OH

⁹Northwestern University, Chicago, IL

¹⁰University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, TX

¹¹The Ohio State University, Columbus, OH

¹²Drexel University, Philadelphia, PA

¹³Wake Forest University Health Sciences, Winston-Salem, NC

¹⁴University of Texas Medical Branch, Galveston, TX

¹⁵Wayne State University, Detroit, MI

Abstract

Objective—The anti-oxidant and proangiogenic protein haptoglobin (Hp) is believed to be important for implantation and pregnancy, although its specific role is not known. The three

Address for Correspondence: Tracey L. Weissgerber, Ph.D., Division of Nephrology & Hypertension, Mayo Clinic, 200 1st St SW, RO-HA-06-675B-5, Rochester, MN 55905, Phone: (507) 266-2844, weissgerber.tracey@mayo.edu.

*Other members of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network are listed in the Appendix.

Declaration of Interests

The authors report no conflicts of interest.

phenotypes (1-1, 2-1 and 2-2) differ in structure and function. Hp 2-2 is associated with increased vascular stiffness in other populations. We examined whether Hp phenotype is associated with abnormal uterine artery Doppler (UAD) in pregnancy.

Methods—We conducted a secondary analysis of a preeclampsia prediction cohort nested within a larger placebo-controlled randomized clinical trial of antioxidants for prevention of preeclampsia. We determined Hp phenotype in 2,184 women who completed UAD assessments at 17 weeks gestation. Women with notching were re-evaluated for persistent notching at 24 weeks gestation. Logistic regression was used to assess differences in UAD indices between phenotype groups.

Results—Hp phenotype did not significantly influence the odds of having any notch ($p=0.32$), bilateral notches ($p=0.72$), or a resistance index ($p = 0.28$) or pulsatility index ($p = 0.67$) above the 90th percentile at 17 weeks gestation. Hp phenotype also did not influence the odds of persistent notching at 24 weeks ($p=0.25$).

Conclusions—Hp phenotype is not associated with abnormal UAD at 17 weeks gestation or with persistent notching at 24 weeks.

Keywords

haptoglobin; pregnancy; vascular resistance; women; race; ethnicity

Introduction

Uterine artery Doppler velocimetry (UAD) is a vascular screening test that identifies pregnant women with an increased risk for maternal-placental syndromes, including preeclampsia, intrauterine growth restriction and preterm birth [1]. Abnormal UAD is typically defined as a notch in the uterine artery velocity waveform at the beginning of diastole, or by a resistance or pulsatility index that exceeds the 90th percentile for gestational age [2–4]. These abnormalities suggest high resistance and reduced elasticity and compliance in the uterine vasculature [5]. Failed systemic vascular adaptation to pregnancy [5], maternal cardiac defects [4] and failed dilatory remodeling of the spiral arteries that supply the placenta [6–8] may contribute to abnormal UAD.

Haptoglobin (Hp) is a powerful anti-oxidant [9] and pro-angiogenic [10] protein that is believed to be important for implantation and pregnancy, although its specific role is not known [11, 12]. Hp sequesters iron by binding free hemoglobin following hemolysis [9]. Certain phenotypes may also effect vascular stiffness [13, 14] and modulate natural killer cell invasiveness [12, 15]. The three Hp genotypes give rise to three distinct phenotypes (Hp 1-1, 2-1 and 2-2; Figure 1S), which differ in size, structure, and function [9]. Hp 2-2 is the weakest anti-oxidant [9]. Hp 2-2 is also associated with increased systemic vascular resistance [14], reduced large and small artery elasticity [14], and increased pulse wave velocity in individuals with Type 2 diabetes [13]. This may contribute to the two-fold increase in cardiovascular event risk in Hp 2-2 diabetics, compared to Hp 1-1 and 2-1 diabetics [16].

Small case-control studies suggest that Hp phenotype may predict adverse pregnancy outcomes, including preeclampsia [17, 18], gestational diabetes [19], and premature rupture of membranes [20]. However, we were unable to confirm a relationship between Hp phenotype and preeclampsia risk in large cohorts of low-risk nulliparous women [21] or women with Type 1 diabetes [22] participating in randomized controlled trials of antioxidants for preeclampsia prevention. This highlights the importance of using large cohort studies when examining Hp phenotype and pregnancy outcome to reduce the likelihood of spurious findings [23].

The potential effects of Hp phenotype on abnormal UAD have not been investigated. Hp 2-2 is associated with increased vascular stiffness in Type 2 diabetes [13, 14], however little is known about Hp phenotype and vascular stiffness in other populations. We conducted a pre-planned secondary analysis to determine whether Hp phenotype was associated with abnormal UAD in the trial of low risk nulliparous women [21]. We hypothesized that Hp 2-2 women would be more likely to have abnormal UAD at 17 weeks gestation and persistent notching at 24 weeks gestation. We tested this hypothesis in a preeclampsia prediction cohort nested within a randomized clinical trial of antioxidants for preeclampsia prevention.

Methods

Study Population

We conducted a secondary analysis of a double-blind, multicenter randomized controlled trial in which nulliparous, low risk women received daily doses of 400 IU of vitamin E and 1000 mg of vitamin C, or placebo, from 9–16 weeks gestation until delivery (NCT 00135707) [24]. The trial was conducted between 2003 and 2008 by 16 centers in the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A subset of 2,434 women who started treatment/placebo by 9–12 weeks gestation were enrolled in a nested preeclampsia prediction cohort (women not in the prediction cohort could start treatment/placebo as late as 16 weeks gestation). Women in the prediction cohort provided extra blood samples at each time point and underwent UAD assessment at 17 weeks gestation. All subjects provided written, informed consent before participating. Hp phenotyping was performed at the University of Pittsburgh (Institutional Review Board approval PRO10010368).

UAD

UAD was performed in women enrolled in the prediction study at approximately 17 weeks gestation. If a notch was present on any waveform, a second ultrasound was scheduled at 24 weeks gestation to identify women with persistent notches. Sonographers completed a certification exam to ensure that procedures were standardized across centers. Doppler examinations were performed transabdominally. If the sonographer could not obtain an adequate transabdominal image, transvaginal Doppler was performed. Three waveforms from the right and left uterine arteries were recorded. The uterine artery was insonated as it entered the uterus, one cm distal to where it crossed the external iliac artery. The resistance index (RI) was calculated as (systolic velocity – diastolic velocity) / systolic velocity. The

pulsatility index (PI) was calculated as (systolic velocity – diastolic velocity) / [(systolic velocity + diastolic velocity) / 2]. The RI and PI of the right and left uterine arteries were averaged. A notch was defined as a clear increase in velocity at the beginning of diastole. UAD indices were calculated at each study site by a sonographer who had completed the study certification exam. Multiples of the median for the RI and PI were calculated as described previously [8]. Expected medians were calculated based on a subject's gestational age, maternal weight and race. A RI or PI greater than the 90th percentile for gestational age was considered abnormal.

Hp Phenotyping

Phenotyping was performed as described previously [18] by individuals who were blinded to patient data. 5 µl serum samples supplemented with human hemoglobin (Sigma-Aldrich, St. Louis, MO) were run on 6% tris-glycine native gels (Invitrogen, Carlsbad, CA). Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA).

Hemolyzed samples and samples with low Hp concentrations were phenotyped by sodium dodecyl sulfate polyacrilamide gel electrophoresis (SDS PAGE) of 1 to 6 µl of serum. Samples were run on 12% tris-glycine gels (Invitrogen, Carlsbad, CA) and transferred to PVDF. PVDF was incubated with blocking solution (tris-buffered saline containing 5% non-fat milk, 0.1% Tween 20), and primary (1:5,000, Polyclonal Rabbit Anti-Human Haptoglobin, DakoCytomation, Carpinteria, CA) and secondary (1:25,000, Goat anti-Rabbit IgG horseradish peroxidase, Millipore) antibodies. Incubations were performed at room temperature for one hour each.

PVDF was stained for peroxidase activity (SuperSignal West Pico Chemiluminescent Substrate, Fisher Scientific, Pittsburgh, PA) and imaged (FlouoroChem Q System, Cell Biosciences, Santa Clara, CA). Hp phenotypes were identified by banding patterns of the Hp-hemoglobin complexes (Figure 1S, native PAGE) or the Hp α_1 and α_2 alleles (SDS PAGE).

Statistical Analysis

Baseline characteristics across phenotypes were compared using the Chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables. Logistic models were used to assess the odds of abnormal UAD at the first Doppler exam and persistent notching at the second exam. All models were adjusted for age, gestational age at Doppler exam, treatment group, characteristics that differed between Hp phenotype groups (age, race, education, and prenatal/multivitamin use at randomization), and BMI, which was associated with UAD indices.

Results

Subjects

The prediction cohort included 2,434 women. We excluded 250 women because pregnancy outcome data were not available (n = 40), the UAD exam was not completed by 21 weeks gestation (n = 206), blood samples were not available (n = 1), or Hp was undetectable (Hp 0,

n = 3). Of the remaining 2,184 women, 49 had the rare 2-1M phenotype. Hp 2-1M individuals produce large amounts of Hp 1-1 and only small amounts of the Hp 2-1 isoforms due to a modification of the α_2 allele (Figure 1S) [9]. The opposite banding pattern is observed in Hp 2-1 individuals, who produce very little Hp 1-1 and large amounts of the Hp 2-1 isoforms. Hp 2-1M women were excluded from statistical analyses of UAD indices due to small sample size. 1,066 women were randomized to receive daily vitamin C and E supplementation. This included 53% of Hp 1-1 women (n = 238), 48% of Hp 2-1 women (n = 488), and 51% of Hp 2-2 women (n = 340). The remaining 1,069 women were randomized to receive placebo.

Phenotype prevalence differed by race (Table 1), and was similar to published values for white, black and Hispanic North Americans [25]. Age increased progressively across the Hp 2-1M, 1-1, 2-1 and 2-2 groups (Table 1). Hp 2-2 women were older and more educated than women with the other phenotypes, and were more likely to report vitamin use at randomization than women with the Hp 1-1 and 2-1 phenotypes. The phenotype groups did not differ with respect to pre-pregnancy BMI, blood pressure at randomization, smoking, history of a previous pregnancy ending prior to 20 weeks, or family history of preeclampsia. Hp 2-2 women were randomized slightly later than Hp 1-1 women, and completed their first UAD assessment slightly earlier than Hp 1-1 and 2-1 women. Although statistically significant, these 1–3 day differences are unlikely to have had any clinical impact.

Subsequent analyses of UAD indices were adjusted for characteristics that differed between the 1-1, 2-1 and 2-2 groups (race, age, education, and vitamin use). The “White” and “Other” groups were pooled for race adjustments, as the phenotype prevalence in the “Other” group was most similar to whites. There were no interactions between Hp phenotype and race for UAD indices. Treatment group (vitamins vs. placebo) did not significantly affect any of the UAD indices examined; therefore treatment groups were pooled for all analyses. Results were not different in when the placebo group (211 Hp 1-1 women, 537 Hp 2-1 women, and 321 Hp 2-2 women) was analyzed alone.

Relationship Between Hp Phenotype and UAD Indices at 17 Weeks Gestation

334 women (15.5%) had notching at 17 weeks gestation. Hp phenotype did not significantly influence the odds of having any notch or bilateral notching (Table 2) after adjusting for age, gestational age at Doppler exam, race, education, vitamin use, body weight and treatment group. The odds of having a RI and PI above the 90th percentile for gestational age did not differ between women of different Hp phenotypes.

Relationship Between Hp Phenotype and Persistent Notching at 24 Weeks Gestation

268 of the 334 women (80.2%) who had notching at 17 weeks gestation returned for a second UAD assessment at 24 weeks gestation (Table 3). Six women with the 2-1M phenotype were excluded. The percentage of women who did not return was not different between Hp phenotype groups (data not shown). Gestational age at the second UAD exam did not differ between the phenotype groups. 84 women (32.1%) who completed the second UAD exam had persistent notching (any notch or bilateral notch). The odds of persistent notching did not differ significantly between women with the Hp 1-1, 2-1 and 2-2

phenotypes ($p=0.25$). Only 22 women (8.2%) had persistent bilateral notches. Statistical analyses were not performed due to small sample size.

Discussion

In contrast to our hypothesis, we found that Hp phenotype was not associated with the prevalence of any notch or bilateral notches, or the odds of having a RI or PI above the 90th percentile for gestational age, at 17 weeks gestation. There was also no relationship between Hp phenotype and persistent notching at 24 weeks gestation. This study extends the existing literature regarding Hp phenotype and pregnancy to include UAD. The large sample size, cohort design, and racial and ethnic diversity of the cohort (50% non-Hispanic white, 25% Hispanic, 23% non-Hispanic black) are significant strengths.

Although Hp is believed to be important for implantation and pregnancy, its functional role is not known [11]. Increases in Hp concentration in the rabbit oviduct and uterus follow the time-course of blastocyst transit, and the blastocyst incorporates maternal Hp into its extra-embryonic matrix [11]. Phenotype effects cannot be examined in the rabbit, as this species only has the Hp 1-1 phenotype [26]. In humans, Hp concentrations in the uterine endometrium increase from the follicular to the luteal phase of the menstrual cycle [27]. The uterine decidua has high Hp concentrations at term [27]. Although Hp concentration depends on phenotype [28], this study did not examine the potential effects of phenotype [27]. Mechanistic studies examining the functional significance of these increases in Hp concentration are needed.

There are several possible explanations for the absence of a relationship between Hp phenotype and UAD indices. One possibility is that the phenotype-dependent differences in Hp's functions do not have clinically significant effects on the processes that affect UAD during pregnancy. Alternatively, the strengths and weaknesses of the phenotypes may offset one another (i.e. the superior antioxidant capacity of Hp 1-1 may be counterbalanced by the vascular and proangiogenic properties of Hp 2-2), such that the overall effect of Hp phenotype is not clinically significant. A third possibility is that the multi-factorial nature of abnormal UAD may obscure any potential effect of Hp phenotype on the individual pathological mechanisms that contribute to abnormal UAD (failed systemic vascular adaptation, deficient spiral artery remodeling and placentation, and/or cardiac defects). This might occur if Hp phenotype only alters the risk of one type of pathology, or if different Hp phenotypes are associated with different pathologies. In this case, tests specific to each individual mechanism (peripheral vascular function testing, placental bed biopsies and echocardiography) would be necessary to detect a potential effect of Hp phenotype. These expensive and time consuming measurements were not feasible in this large cohort.

Most research examining the relationship between Hp phenotype and adverse pregnancy outcomes focuses on preeclampsia [17, 18, 29, 30]. The largest case-control studies suggested that Hp 1-1 was associated with a lower preeclampsia risk compared to Hp 2-1 [18], or Hp 2-1 and 2-2 [17]. However, we found no relationship between Hp phenotype and preeclampsia risk in 4,500 women from the present trial, suggesting that the results of small case-control studies may have been spurious findings [21]. This highlights the need for

large, prospective studies [21, 23]. Two small case-control studies examined the potential impact of Hp phenotype on other adverse pregnancy outcomes [19, 20]. Austrian women with gestational diabetes were more likely to have the Hp α_2 allele than women with uncomplicated pregnancies [19]. In contrast, Korean women with premature rupture of membranes were more likely to have the Hp 1-1 phenotype (23% vs. 8%) than women with uncomplicated pregnancies [20]. The preeclampsia data suggest that these findings should be verified in large cohorts. The prediction cohort included too few women with gestational diabetes ($n = 83$) to examine this outcome. Premature rupture of membranes ($n = 287$) will be examined in a future study.

Limitations

This study has two important limitations. A notch was defined as a clear increase in velocity at the beginning of diastole, rather than by measured criteria. However, all sonographers completed a certification exam to ensure that waveforms were read consistently across sites. Second, UAD was assessed at approximately 17 weeks gestation, and results may differ at other gestational ages. This gestational age was selected for the original study because several large prospective studies reported that abnormal UAD in the second trimester or late first trimester was useful in predicting preeclampsia [1]. Early reports also suggested that Hp phenotype was associated with preeclampsia risk [17, 18]; hence we sought to examine the potential effects of Hp phenotype on UAD both as a vascular test, and as a potential mechanism leading to increased preeclampsia risk. However, subsequent analyses demonstrated that abnormal UAD had poor sensitivity for predicting preeclampsia in this cohort [8], and we were also unable to confirm a relationship between Hp phenotype and preeclampsia risk [21].

In conclusion, Hp phenotype did not identify women at increased risk of abnormal UAD in a racially diverse pregnancy cohort of low risk, nulliparous women. Large cohorts are needed to confirm the results of small case-control studies suggesting that Hp phenotype significantly affects the risk of gestational diabetes [19] and premature rupture membranes [20]. Mechanistic studies are also needed to identify the specific role of Hp in implantation and pregnancy, and to examine the potential role of Hp phenotype.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank James M. Roberts for his extensive involvement in this project, and the subcommittee members who participated in protocol development and coordination between clinical research centers (Sabine Bousleiman, Margaret Cotroneo), protocol/data management and statistical analysis (Rebecca G. Clifton, Elizabeth Thom), and protocol development and oversight (James M. Roberts, Kenneth J. Leveno, Catherine Y. Spong, Gail D. Pearson).

The project described was supported by grants from the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) [P01 HD030367, HD34208, HD27869, HD40485, HD40560, HD40544, HD34116, HD40512, HD21410, HD40545, HD40500, HD27915, HD34136, HD27860, HD53118, HD53097, HD27917, and HD36801]; the National Heart, Lung, and Blood Institute; and the National Center for Research Resources [M01 RR00080, UL1 RR024153, UL1 RR024989] and its contents do not necessarily represent the official view of NICHD, NHLBI, NCRR or NIH. Dr. Tracey Weissgerber was supported by a Canadian Institute of

Health Research Fellowship, an Amy Roberts Health Promotion Research Award and the Office of Women's Health Research (Building Interdisciplinary Careers in Women's Health award K12HD065987).

References

1. Papageorgiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. *Best Pract Res Clin Obstet Gynaecol.* 2004; 18:383–396. [PubMed: 15183134]
2. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. *BMJ.* 342:d1875. [PubMed: 21474517]
3. Yu CK, Smith GC, Papageorgiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. *Am J Obstet Gynecol.* 2005; 193:429–436. [PubMed: 16098866]
4. Melchiorre K, Sutherland GR, Liberati M, Bhide A, Thilaganathan B. Prevalence of maternal cardiac defects in women with high-resistance uterine artery Doppler indices. *Ultrasound Obstet Gynecol.* 2011; 37:310–316. [PubMed: 20882562]
5. Acacio GL. Uterine artery Doppler patterns in abdominal pregnancy. *Ultrasound Obstet Gynecol.* 2002; 20:194–196. [PubMed: 12153673]
6. Fraser R, Whitley GS, Johnstone AP, Host AJ, Sebire NJ, Thilaganathan B, Cartwright JE. Impaired decidual natural killer cell regulation of vascular remodelling in early human pregnancies with high uterine artery resistance. *J Pathol.* 2012; 228:322–332. [PubMed: 22653829]
7. Prefumo F, Sebire NJ, Thilaganathan B. Decreased endovascular trophoblast invasion in first trimester pregnancies with high-resistance uterine artery Doppler indices. *Hum Reprod.* 2004; 19:206–209. [PubMed: 14688183]
8. Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Grobman WA, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y, Anderson GD. The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population. *Obstetrics and gynecology.* 2012; 120:815–822. [PubMed: 22996099]
9. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul FM, Asaf R, Farbstein D, Pollak M, Soloveichik YZ, Strauss M, Alshiek J, Livshits A, Schwartz A, Awad H, Jad K, Goldenstein H. Haptoglobin: basic and clinical aspects. *Antioxid Redox Signal.* 12:293–304. [PubMed: 19659435]
10. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. *J Clin Invest.* 1993; 91:977–985. [PubMed: 7680672]
11. Herrler A, Krusche CA, Muller-Schottle F, Beier HM. Haptoglobin expression and release by rabbit oviduct and endometrium, its localization in blastocyst extra-embryonic matrix and fluid during preimplantation time. *Hum Reprod.* 2004; 19:2730–2737. [PubMed: 15388678]
12. Herrler A, von Rango U, Beier HM. Embryo-maternal signalling: how the embryo starts talking to its mother to accomplish implantation. *Reprod Biomed Online.* 2003; 6:244–256. [PubMed: 12676010]
13. Frand J, Borislavsky A, Boaz M, Matas Z, Shargorodsky M. Does adiponectin level explain the atherogenic properties of Hp 2-2 phenotype in type 2 diabetic patients? *Atherosclerosis.* 2013; 226:146–148. [PubMed: 23177015]
14. Shor M, Boaz M, Gavish D, Wainshtein J, Matas Z, Shargorodsky M. Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus. *Am J Cardiol.* 2007; 100:1767–1770. [PubMed: 18082523]
15. Nauta U, Beier HM, Herrler A. Abstract: Haptoglobin in extracellular matrices reduce the adhesion/invasion of NK (CD11b+) cells. *Reproduction Abstracts Series.* 2002; 29:21.
16. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. *Journal of the American College of Cardiology.* 2002; 40:1984–1990. [PubMed: 12475459]

17. Sammour RN, Nakhoul FM, Levy AP, Miller-Lotan R, Nakhoul N, Awad HR, Gonen R, Ohel G. Haptoglobin phenotype in women with preeclampsia. *Endocrine*. 2010; 38:303–308. [PubMed: 20972727]
18. Weissgerber TL, Roberts JM, Jeyabalan A, Powers RW, Lee M, Datwyler SA, Gandle RE. Haptoglobin phenotype, angiogenic factors, and preeclampsia risk. *Am J Obstet Gynecol*. 2012; 206:358, e310–e318. [PubMed: 22340942]
19. Mustafa S, Vukovich T, Prikoszovich T, Winzer C, Schneider B, Esterbauer H, Wagner O, Kautzky-Willer A. Haptoglobin phenotype and gestational diabetes. *Diabetes Care*. 2004; 27:2103–2107. [PubMed: 15333469]
20. Cho JK, Kim YH, Park IY, Shin JC, Oh MK, Park SJ, Kim NH, Kim IS. Polymorphism of haptoglobin in patients with premature rupture of membrane. *Yonsei Med J*. 2009; 50:132–136. [PubMed: 19259359]
21. Weissgerber TL, Gandle RE, Mcgee PL, Spong CY, Myatt L, Leveno KJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y. Haptoglobin Phenotype, Preeclampsia Risk and the Efficacy of Vitamin C and E Supplementation to Prevent Preeclampsia in a Racially Diverse Population. *PLoS One*. 2013; 8:e60479. [PubMed: 23573260]
22. Weissgerber TL, Gandle RE, Roberts JM, Patterson CC, Holmes VA, Young IS, McCance DR. Haptoglobin phenotype and preeclampsia incidence in women with Type 1 Diabetes supplemented with Vitamins C and E. *British Journal of Obstetrics and Gynecology*. 2013; 120:1192–1199.
23. Goldenstein H, Levy N, Levy A. Involvement of haptoglobin in prevention of oxidative stress caused by hemoglobin in preeclampsia. *Advances in Bioscience and Biotechnology*. 2012; 3:1037–1042.
24. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, Pearson GD, Wapner RJ, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Smith WJ, Saade G, Sorokin Y, Anderson GB. Vitamins C and E to prevent complications of pregnancy-associated hypertension. *N Engl J Med*. 2010; 362:1282–1291. [PubMed: 20375405]
25. Gaensslen RE, Bell SC, Lee HC. Distributions of genetic markers in United States populations: III. Serum group systems and hemoglobin variants. *J Forensic Sci*. 1987; 32:1754–1774. [PubMed: 3480937]
26. Langlois MR, Delanghe JR, De Buyzere ML, Bernard DR, Ouyang J. Effect of haptoglobin on the metabolism of vitamin C. *Am J Clin Nutr*. 1997; 66:606–610. [PubMed: 9280180]
27. Berkova N, Lemay A, Dresser DW, Fontaine JY, Kerizit J, Goupil S. Haptoglobin is present in human endometrium and shows elevated levels in the decidua during pregnancy. *Mol Hum Reprod*. 2001; 7:747–754. [PubMed: 11470862]
28. Cheng TM, Pan JP, Lai ST, Kao LP, Lin HH, Mao SJ. Immunochemical property of human haptoglobin phenotypes: determination of plasma haptoglobin using type-matched standards. *Clin Biochem*. 2007; 40:1045–1056. [PubMed: 17583688]
29. Depypere HT, Langlois MR, Delanghe JR, Temmerman M, Dhont M. Haptoglobin polymorphism in patients with preeclampsia. *Clin Chem Lab Med*. 2006; 44:924–928. [PubMed: 16879055]
30. Raijmakers MT, Roes EM, te Morsche RH, Steegers EA, Peters WH. Haptoglobin and its association with the HELLP syndrome. *J Med Genet*. 2003; 40:214–216. [PubMed: 12624142]

Appendix

In addition to the authors, other members of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network are as follows:

University of Pittsburgh, Pittsburgh, PA – J. Roberts, S. Caritis, T. Kamon (deceased), M. Cotroneo, D. Fischer

University of Utah, Salt Lake City, UT – P. Reed, S. Quinn (LDS Hospital), V. Morby (McKay-Dee Hospital), F. Porter (LDS Hospital), R. Silver, J. Miller (Utah Valley Regional Medical Center), K. Hill

University of Alabama at Birmingham, Birmingham, AL – D.J. Rouse, A. Northen, P. Files, J. Grant, M. Wallace, K. Bailey

Columbia University, New York, NY – S. Bousleiman, R. Alcon, K. Saravia, F. Loffredo, A. Bayless (Christiana), C. Perez (St. Peter's University Hospital), M. Lake (St. Peter's University Hospital), M. Talucci

University of North Carolina at Chapel Hill, Chapel Hill, NC – K. Boggess, K. Dorman, J. Mitchell, K. Clark, S. Timlin

Case Western Reserve University-MetroHealth Medical Center, Cleveland, OH – J. Bailit, C. Milluzzi, W. Dalton, C. Brezine, D. Bazzo

University of Texas Southwestern Medical Center, Dallas, TX – K. Leveno, J. Sheffield, L. Moseley, M. Santillan, K. Buentipo, J. Price, L. S. Hermann, C. Melton, Y. Gloria-McCutchen, B. Espino

Northwestern University, Chicago, IL – M. Dinsmoor (NorthShore University HealthSystem), T. Matson-Manning, G. Mallett

University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, TX – S. Blackwell, K. Cannon, S. Lege-Humbert, Z. Spears

Brown University, Providence, RI – M. Carpenter, J. Tillinghast, M. Seebeck

The Ohio State University, Columbus, OH – J. Iams, F. Johnson, S. Fyffe, C. Latimer, S. Frantz, S. Wylie

Drexel University, Philadelphia, PA – M. Talucci, M. Hoffman (Christiana), J. Benson (Christiana), Z. Reid, C. Tocci

Wake Forest University Health Sciences, Winston-Salem, NC – P. Meis, M. Swain

Oregon Health & Science University, Portland, OR – J. Tolosa, W. Smith, L. Davis, E. Lairson, S. Butcher, S.

Maxwell, D. Fisher

University of Texas Medical Branch, Galveston, TX – J. Moss, B. Stratton, G. Hankins, J. Brandon, C. Nelson-Becker, G. Olson, L. Pacheco

Wayne State University, Detroit, MI – G. Norman, S. Blackwell, P. Lockhart, D. Driscoll, M. Dombrowski

The George Washington University Biostatistics Center, Washington, DC – E. Thom, R. Clifton, T. Boekhoudt, L. Leuchtenburg

National Heart, Lung, and Blood Institute, Bethesda, MD – V. Pemberton, J. Cutler, W. Barouch

Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD – C. Spong, S. Tolivaisa

MFMU Steering Committee Chair (*University of Texas Medical Center, Galveston, TX*) – G.D. Anderson, M.D.

Table 1

Subject characteristics

Subject Characteristics	Hp 1-1 (n = 449)	Hp 2-1 (n = 1025)	Hp 2-2 (n = 661)	Hp 2-1M (n = 49)	p
Age – years	22.7 ± 4.5	23.4 ± 4.8 ^a	24.3 ± 4.9 ^{a,b}	20.6 ± 3.4 ^{a,b,c}	<0.01
Gestational age at randomization – week	11.4 ± 1.1	11.4 ± 1.1	11.5 ± 1.0 ^a	11.0 ± 1.1 ^{a,b,c}	0.01
Gestational age at Doppler exam – week	17.0 ± 1.1	17.0 ± 1.2	16.8 ± 1.1 ^{a,b}	17.4 ± 1.2 ^{a,b,c}	<0.01
Race or ethnic group - n (% within phenotype)					<0.01
White	166 (37%)	509 (50%)	410 (62%)	3 (6%)	
Black	144 (32%)	221 (22%)	103 (16%)	42 (86%)	
Hispanic	133 (30%)	276 (27%)	132 (20%)	3 (6%)	
Other	6 (1%)	19 (2%)	16 (2%)	1 (2%)	
Significance	^a	^a	^{a,b}	^{a,b,c}	
Pre-pregnancy body mass index - kg/m ²	25.8 ± 6.5	25.3 ± 5.8	25.4 ± 6.1	27.1 ± 6.9	0.33
Smoked during pregnancy - n (%)	80 (18%)	162 (16%)	111 (17%)	7 (14%)	0.77
Education - years	12.7 ± 2.6	12.9 ± 2.6	13.4 ± 2.5 ^{a,b}	12.3 ± 1.8 ^c	<0.01
Prenatal/multivitamin use prior to randomization - n (%)	332 (74%)	798 (78%)	562 (85%) ^{a,b}	43 (88%) ^a	<0.01
Previous pregnancy - n (%)	91 (20%)	225 (22%)	157 (24%)	13 (27%)	0.48
Family history of preeclampsia - n (%)	63 (14%)	139 (14%)	82 (12%)	6 (12%)	0.86
Blood pressure at entry (9–12 weeks) - mmHg	109 ± 10	110 ± 10	110 ± 10	110 ± 11	0.50
Systolic					
Diastolic	65 ± 8	66 ± 8	67 ± 8	64 ± 9	0.11

Three subjects with no detectable Hp (Hp 0) were excluded from the analysis. Values are mean ± SD or n (%).

Significant difference (p<0.05) from: ^aHp 1-1, ^bHp 2-1, ^cHp 2-2.

Table 2

Hp phenotype and abnormal UAD at the first exam

Outcome	Hp 1-1 (n = 449)	Hp 2-1 (n = 1025)	Hp 2-2 (n = 661)	OR (95% CI)		p ^a
				Hp 1-1	Hp 2-1	
Any Notch ^b	70/433 (16.2%)	158/1004 (15.7%)	95/651 (14.6%)	1.29 (0.91, 1.82)	1.18 (0.89, 1.57)	0.32
Bilateral Notch ^c	27/435 (6.2%)	63/1007 (6.3%)	36/652 (5.5%)	1.19 (0.70, 2.01)	1.18 (0.77, 1.81)	0.72
RI >90 th Percentile ^a	38/449 (8.5%)	108/1025 (10.5%)	61/661 (9.2%)	0.87 (0.56, 1.34)	1.19 (0.85, 1.66)	0.28
PI >90 th Percentile ^d	41/448 (9.2%)	107/1023 (10.5%)	65/661 (9.8%)	0.89 (0.58, 1.36)	1.06 (0.76, 1.48)	0.67

Values are n/total (%), or OR (95% CI) with Hp 2-2 as the reference group. Abbreviations: OR, odds ratio; CI, confidence interval.

^a Adjusted for age, gestational age at Doppler exam, race, education, vitamin use, pre-pregnancy BMI and treatment group. 38 women with missing pre-pregnancy BMI data were excluded from all models.^b Nine women with missing data for any notch were excluded. Only 323 of the 334 women with notching are included in the table, as 8 women had the 2-1M phenotype and 3 women were missing pre-pregnancy BMI.^c Three women with missing bilateral notch data were excluded.^d Multiples of the median for the RI and PI were calculated to determine whether values exceeded the 90th percentile for gestational age.

Table 3

Hp phenotype and persistent notching at 24 weeks gestation

Variable	Hp 1-1 (n =53)	Hp 2-1 (n =134)	Hp 2-2 (n =75)
Gestational age at 1 st UAD assessment	16.9 ± 1.0	16.6 ± 1.1	16.6 ± 0.92
Gestational age at 2 nd UAD assessment	24.2 ± 1.0	24.3 ± 0.9	24.1 ± 0.9
Persistent notches (any notch or bilateral notches) n (%)	17 (32.1%)	49 (36.6%)	18 (24.0%)
OR (95% CI)*	1.16 (0.50, 2.66)	1.68 (0.87, 3.26)	1

Values are mean ± standard deviation unless otherwise indicated. Abbreviations: OR, odds ratio; CI, confidence interval. 268 women with notches at the first assessment returned for a 2nd UAD assessment. Six women with the Hp 2-1M phenotype were excluded.

^a Adjusted for age, gestational age at Doppler exam, race, education, vitamin use, pre-pregnancy BMI and treatment group.